Chen P S, Chang H H, Huang C-C, Lee C C, Lee S-Y, Chen S-L, Huang S-Y, Yang Y K, Lu R-B
Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Addiction Research Center, National Cheng Kung University, Tainan, Taiwan.
Pharmacogenomics J. 2017 Mar;17(2):155-161. doi: 10.1038/tpj.2015.96. Epub 2016 Feb 9.
This longitudinal study aimed to investigate the associations between the polymorphisms of guanine nucleotide-binding protein subunit β-3 (GNB3) C825T and metabolic disturbance in bipolar II disorder (BP-II) patients being treated with valproate (VPA). A 100 BP-II patients received a 12-week course of VPA treatment, and their body weight and metabolic indices were measured. At baseline, the GNB3 C825T polymorphisms were associated with the triglyceride level (P=0.032) in BP-II patients. During the VPA treatment course, the polymorphisms were not only associated with body mass index (BMI) and waist circumference (P-values=0.009 and 0.001, respectively), but also with total cholesterol, triglyceride, low-density lipoprotein and leptin levels (P-values=0.004, 0.002, 0.031 and 0.015, respectively). Patients with the TT genotype had a lower BMI, smaller waist circumference, and lower levels of lipids and leptin than those with the CT or CC genotypes undergoing the VPA treatment course.
这项纵向研究旨在调查接受丙戊酸盐（VPA）治疗的双相II型障碍（BP-II）患者中鸟嘌呤核苷酸结合蛋白β-3亚基（GNB3）C825T基因多态性与代谢紊乱之间的关联。100名BP-II患者接受了为期12周的VPA治疗疗程，并测量了他们的体重和代谢指标。在基线时，GNB3 C825T基因多态性与BP-II患者的甘油三酯水平相关（P=0.032）。在VPA治疗疗程中，该基因多态性不仅与体重指数（BMI）和腰围相关（P值分别为0.009和0.001），还与总胆固醇、甘油三酯、低密度脂蛋白和瘦素水平相关（P值分别为0.004、0.002、0.031和0.015）。与接受VPA治疗疗程的CT或CC基因型患者相比，TT基因型患者的BMI更低、腰围更小，脂质和瘦素水平也更低。
